Shows / BioSpace
BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Episodes
BioSpaceStability, speed and strategy: Inside Australia’s early‑stage edge
In this episode of Denatured, you’ll hear from Jerome Barley, commercial director at Avion Medical and Ryan Klein, vice president, business development, US and…
BioSpaceData leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
Merck stole the show at the European Society for Medical Oncology (ESMO) annual conference, with new data on its Moderna-partnered personalized cancer vaccine…
BioSpaceWhy investors are taking another look at kidney disease
In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long…
BioSpaceDisc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners
China cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems…
- BioSpace
Bonus: Q3 2026 Job Market Update
BioSpace Vice President Chantal Dresner and Angela Gabriel, content manager, life sciences careers, cover what happened in the biopharma job market during the…
BioSpaceThe decisions behind scientific progress
In this episode of Denatured, sponsored by Cytiva, Jennifer Smith-Parker speaks to Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions at Cytiva. In this…
BioSpaceJ&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win…
BioSpaceBeyond equity: Why venture debt is reshaping European biotech
In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture…
BioSpaceGenmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell…
BioSpaceThe race for access: How the FAIR Act could reclaim U.S. biotech leadership
In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into…
BioSpaceAstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year…
BioSpaceHow radioligand therapy is rewriting cancer care
In this episode of Denatured presented by Curium, Jennifer Smith-Parker speaks to Mike Patterson, CEO North America and Professor Sabine Brookman-May, vice…
BioSpaceNovo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
Novo plans to hit $23B in revenue by 2035, has further reduced its workforce by 4,000 and is boosting manufacturing capacity for its Wegovy pill, but investors…
BioSpaceWhen vision fades: Rethinking wet AMD and the durability gap
In this episode of Denatured, you’ll hear Philip Jacob Rosenfeld, professor of Ophthalmology at the University of Miami Health System and Bascom Palmer Eye…
BioSpaceFDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
The FDA held a public forum on Monday to discuss the future of psychedelic therapeutics, followed by a meeting on Wednesday regarding recommendations for…
BioSpaceThe supply chain fault lines of modern pharma
In this episode of Denatured, sponsored by SK Pharmteco, Jennifer Smith-Parker speaks to Arvind Singh, vice president and global head of supply chain. In this…
BioSpaceNovo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took…
BioSpaceBreaking borders: Building biotech scale in Benelux
In this episode of Denatured, you’ll listen to Christina Takke, managing partner at V-Bio Ventures and Mariette van der Velden-Roesink, founding partner at…
BioSpaceNovartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate safety signals; Revolution Medicines…
BioSpaceFragile X at a turning point: Breaking through the clinical bottleneck
In this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and Jordi Fàbrega, co-founder & CEO at…
BioSpaceCapricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed
FDA extends its review of Capricor Therapeutics’ Duchenne muscular dystrophy cell therapy as an unhappy shareholder advocates for change; Merck and Moderna…
BioSpaceRewriting the rules of CMV prevention
In this episode of Denatured, you’ll hear from Ian McGowan, Chief Medical Officer at Synklino and James Hunter, associate professor of transplantation at…
BioSpaceAmylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s…
BioSpaceThe Italian inflection point: Clinical strength, culture and capital
In this episode of Denatured, you’ll hear from Diana Saraceni, founder and managing partner at Panakès Partners and Fabrizio Calisti, medical director at…
BioSpaceReplimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
After two rejections, Replimune has made it across the regulatory finish line with its twice-rejected therapy for advanced melanoma. Meanwhile, the last of the…
BioSpaceRumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile…
BioSpaceThe next treatment-resistant depression paradigm
In this episode of Denatured, you’ll hear from Hans Eriksson, chief medical officer at FundaMental Pharma and Steve Levine, chief patient officer at Compass…
BioSpaceRumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile…
BioSpaceLife after the lead asset: Advancing an early-stage pipeline
In this episode of Denatured presented by Arvinas, Jennifer Smith-Parker speaks to Arvinas President and CEO Randy Teel about the strategic discipline and…
BioSpaceCapricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
The FDA published briefing documents ahead of advisory committee meetings for Capricor Therapeutics’ Duchenne muscular dystrophy therapy and Replimune’s…
BioSpaceNordic biotech’s next act: From fragmentation to global force
In this episode of Denatured, you’ll hear from Ester Sklarsky, principal at Sound Bioventures and João Ribas, partner at Novo Holdings Seed Investments. In…
BioSpaceQ2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear…
BioSpaceThe future of pain relief: Exploring opioid alternatives
In this episode of Denatured, you’ll hear from Lance Alstodt, chairman and CEO at Biorestorative Therapies, and Paul Mieyal, chief business officer at South…
BioSpaceBiogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
Biogen’s new data, presented at the Alzheimer's Association International Conference, supports a tau-focused approach to the intractable neurodegenerative…
BioSpaceBonus: Q2 2026 Job Market Update
In this bonus episode, BioSpace Managing Editor Jef Akst and Angela Gabriel, content manager, life sciences careers, look at the Q2 job market and discuss…
BioSpaceFrom sequence to scale: Gene editing’s new era in biologics manufacturing
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack…
BioSpaceVertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil
A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IPOs…
BioSpaceSentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
The vibe at BIO 2026 in San Diego last week was overwhelmingly positive, with attendees observing noticeable changes at the FDA and an uptick in dealmaking and…
BioSpaceThe Golden Triangle and the gaps: Rethinking UK biotech
In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll hear from Hakan Goker, managing director at M…
BioSpaceAbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more
This year has been partly defined by a return to M&A. In the first quarter of 2026, biopharma spent nearly $47 billion in acquisitions across 19 deals, and…
BioSpaceFrom fragile skin to living medicine: Lessons from RDEB
In this episode of Denatured, you'll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We…
BioSpaceModerna’s FDA adcomm, IPO mania, biopharma layoffs, more
Moderna’s mRNA-based flu vaccine made headlines in February when the FDA declined to even review the application. Days later, the agency reversed course…
BioSpacePortugal, Spain and the new biotech frontier
In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll hear from Hannah Franklin, associate at Biovance…
BioSpaceLilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence
Everything came up roses for Eli Lilly at the American Diabetes Association, as the pharma boasted positive results for its new pill Foundayo and next-gen…
BioSpaceRethinking hair loss treatment
In this episode of Denatured, you'll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology…
BioSpaceASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck
At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past weekend, packed plenary sessions from Revolution Medicines and Summit…
BioSpaceFrance’s biotech ecosystem: science, capital and scale
In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll be hearing from Ksenija Pavletic, partner and…
BioSpaceLilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds
Eli Lilly has been as acquisitive as ever, striking five new deals in the past week alone. On Tuesday, the company dove into the deep end of vaccine…
BioSpaceInside Germany’s biotech capital infrastructure and innovation engine
In this episode of Denatured, as part of our series of the European life science investment ecosystem, you'll be hearing from Regina Hodits, managing director…
BioSpaceFDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum
FDA Commissioner Marty Makary officially resigned last week following reports of his ouster. Then, the acting directors for the agency’s two main review units…
BioSpaceFrom MSCs to iPSCs: building the cell therapy future
In this episode of Denatured, you'll be hearing from Miguel Forte, president of the International Society for Cell and Gene Therapy (ISCT), and John Ellis…
BioSpaceMakary’s out at FDA, Sanofi’s priority voucher issues, top exec pay
Moments after recording this episode of The Weekly, FDA Commissioner Marty Makary announced his resignation. Reports first circulated last Friday that…
BioSpaceFibrosis, IPF and the search for better therapies
In this episode of Denatured, you'll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder & Chief Medical Officer of…
BioSpacePfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening
First quarter earnings continue to roll in, with Pfizer, Eli Lilly, Amgen and more reporting in the past week. While Pfizer beat consensus estimates, it wasn’t…
BioSpaceWhat makes life science angel investment work?
In this episode of Denatured, you'll be hearing from Yaniv Sneor, founder of the Mid Atlantic Bio Angels and Alex Pederson, an investor at Mid Atlantic Bio…
BioSpaceQ1 earnings take off, Lilly strikes deals, Regeneron notches historic approval, FDA raises questions
First quarter earnings are coming in at a rapid pace, with Sanofi and Novartis defending patents for Dupixent and Lutathera, respectively, and Sanofi welcoming…
BioSpaceThe next era of diabetes management
In this episode of Denatured, you'll be hearing from Dr. Sarah Howell, CEO at Arecor Therapeutics and Dr. Wendy S. Lane, clinical endocrinologist and…
BioSpaceTrump’s psychedelics push, Lilly’s up to $7B CAR T deal, Replimune’s saga and Denali’s big win
After entering the CAR T arena in February, Eli Lilly jumped onto the in vivo bandwagon, penning a deal worth up to $7 billion for Kelonia Therapeutics and its…
BioSpaceFunding the Future of European Biotech
In this episode of Denatured, you'll be hearing from Edoardo Negroni, co-founder & managing partner at AurorA-TT and Naveed Siddiqi, senior partner, Venture…
BioSpaceJ&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer
Johnson & Johnson kicked off Q1 earnings season with a “modest” beat, raking in $24.1 billion in sales as it targets $100 billion in revenue in 2026. J&J, as…